HIV drug shows promise against Hard-to-Treat vulvar cancer
NCT ID NCT04169763
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether adding the HIV drug nelfinavir to standard chemotherapy (cisplatin) and radiation can safely treat advanced vulvar cancer that has spread and cannot be surgically removed. About 25 adults with stage II-IVA vulvar cancer will take part. The main goal is to find the best dose of nelfinavir and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II VULVAR CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.